Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
| ▸ | WDR5 | P61964 | 5/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.33 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.33 |
| ▸ | FGFR3 | P22607 | 4/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.33 |
| ▸ | TIPARP | Q7Z3E1 | 4/20 | 0.32 |
| ▸ | ACVR1 | Q04771 | 3/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30940689 | 1.00 | GPR119 (0.36) | GPR119WDR5RIPK1FGFR2FGFR3 | |
| SCHEMBL24968389 | 0.91 | TIPARP (0.40) | GPR119WDR5RIPK1FGFR2FGFR3 | |
| SCHEMBL24968397 | 0.91 | TIPARP (0.40) | GPR119WDR5RIPK1FGFR2FGFR3 | |
| SCHEMBL24968352 | 0.91 | TIPARP (0.40) | GPR119WDR5RIPK1FGFR2FGFR3 | |
| SCHEMBL24968357 | 0.91 | GPR119 (0.37) | GPR119WDR5RIPK1FGFR2FGFR3 | |
| SCHEMBL24968240 | 0.86 | ACACB (0.35) | GPR119WDR5TIPARPKCNH2 | |
| SCHEMBL24968241 | 0.86 | ACACB (0.35) | GPR119WDR5TIPARPKCNH2 | |
| SCHEMBL24968457 | 0.86 | ACACB (0.35) | GPR119WDR5TIPARPKCNH2 | |
| SCHEMBL24967955 | 0.85 | TIPARP (0.42) | GPR119TIPARPKCNH2 | |
| SCHEMBL24968931 | 0.85 | GPR119 (0.37) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240351997-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | SHANGHAI QILU PHARMACEUTICAL RESEARCH AND DEVELOPMENT CENTRE LTD. (CN) | 2024-10-24 | — | — | US | disclosed |
| WO-2023006013-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | 上海齐鲁制药研究中心有限公司 | 2023-02-02 | — | — | WO | disclosed |
| WO-2023006013-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | 上海齐鲁制药研究中心有限公司 | 2023-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240351997-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | PARP6, PARP4, PARP3 | GPR119 2414/4885WDR5 705/4885RIPK1 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.